.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD24_SitagliptinAndErtugliflo.SitagliptinAndErtugliflo .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD24_SitagliptinAndErtugliflo.SitagliptinAndErtugliflo| name: | SitagliptinAndErtugliflozin | |
| ATC code: | A10BD24 | |
| route: | oral | |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 198 | L |
| clearance: | 350 | ml/min |
| other parameters in model implementation | ||
Sitagliptin and ertugliflozin is a fixed-dose combination oral antidiabetic medication used for the treatment of type 2 diabetes mellitus. Sitagliptin is a DPP-4 inhibitor while ertugliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. The combination provides glycemic control through complementary mechanisms. The combination is approved and marketed in various countries for adult patients with type 2 diabetes.
Estimated pharmacokinetic parameters for healthy adult subjects following oral administration. No published combined PK model for this exact fixed-dose combination, values are based on individual published PK properties of sitagliptin and ertugliflozin single agents.